NCT07349160 2026-01-16
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1 Recruiting
Clinical Trials
8 trialsNCT07285395 2025-12-16
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
NCT06840821 2025-12-02
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
Phase 1/2 Recruiting
NCT06719362 2025-07-10
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
Phase 1 Recruiting
NCT07046650 2025-07-01
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Fudan University
Phase 2 Recruiting
NCT06954558 2025-05-01
GUARDIAN
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Recruiting
NCT06801470 2025-02-07
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
Phase 1 Recruiting
NCT06329206 2024-07-08
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
Phase 1 Recruiting